LIPO-GLYCOPEPTIDE CLEAVABLE DERIVATIVES AND USES THEREOF
The present invention provides certain lipo-glycopeptide cleavable derivatives and methods for using the same for the treatment of bacterial infections, for example, pulmonary bacterial infections. The LGPC derivatives include a cleavable moiety that in certain embodiments, is designed to allow for cellular uptake and/or a more rapid clearance of the glycopeptide metabolite (i.e., the cleaved glycopeptide) from the site of administration (e.g., the lung) as compared to the uncleaved LGPC. The bacterial infection can comprise intracellular bacteria, planktonic bacteria, bacteria present in a biofilm, or a combination thereof.
1 . (canceled)
2 . A compound of Formula (II), or a pharmaceutically acceptable salt thereof:
wherein,
R 1 is —(CH 2 ) n1 —C(O)—O—(CH 2 ) n2 —CH 3 ; —(CH 2 ) n1 —C(O)—NH—(CH 2 ) n2 —CH 3 ; —C(O—CH 2 ) n2 —CH 3 ;
(CH 2 ) n1 —NH—C(O)—(CH 2 ) n2 —CH 3 ; —(CH 2 ) n1 —O—C(O)—(CH 2 ) n2 —CH 3 ; —(CH 2 ) n1 —O—C(O)—NH—(CH 2 ) n2 —CH 3 ; —(CH 2 ) n1 —O—(CO)—O—(CH 2 ) n2 —CH 3 or —(CH 2 ) n1 —NH—C(O)—O—(CH 2 ) n2 —CH 3 ;
R 2 is
R 3 is H or
R 4 is OH or NH—(CH 2 ) q —R 5 ;
R 5 is —N(CH 3 ) 2 , —N + (CH 3 ) 3 , —N + (CH 3 ) 2 (n-C 14 H 29 ), or
and
R′ is diethanolamine, a monosaccharide, disaccharide, amino acid, or peptide, wherein the peptide has from 2 to 5 amino acids;
n1 is 1, 2, 3, 4 or 5;
n2 is 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15;
n3 is 1, 2 or 3; and
q is 1, 2, 3, 4, or 5.
3 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 3 is H.
4 . (canceled)
5 . The compound of claim 2 , wherein R 4 is OH.
6 - 23 . (canceled)
24 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —(CH 2 ) n1 —NH—C(O)—(CH 2 ) n2 —CH 3 .
25 - 26 . (canceled)
27 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 1 is —(CH 2 ) n1 —C(O)—NH—(CH 2 ) n2 —CH 3 .
28 - 33 . (canceled)
34 . The compound of claim 24 , or a pharmaceutically acceptable salt thereof, wherein n1 is 2.
35 . (canceled)
36 . The compound of claim 27 , or a pharmaceutically acceptable salt thereof, wherein n1 is 2.
37 - 43 . (canceled)
44 . The compound of claim 34 , or a pharmaceutically acceptable salt thereof, wherein n2 is 10.
45 . The compound of claim 36 , or a pharmaceutically acceptable salt thereof, wherein n2 is 11.
46 - 48 . (canceled)
49 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein n3 is 1.
50 - 51 . (canceled)
52 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R′ is diethanolamine.
53 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R′ is an amino acid.
54 . The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R′ is a dipeptide.
55 - 58 . (canceled)
59 . The compound of claim 53 , or a pharmaceutically acceptable salt thereof, wherein the amino acid is D-alanine, β-alanine, aspartic acid, glutamic acid, iminodiacetic acid, or glycine.
60 - 66 . (canceled)
67 . A method of treating a bacterial infection in a patient in need of treatment, comprising administering to the patient a composition comprising an effective amount of compound of claim 2 , or a pharmaceutically acceptable salt thereof.
68 - 81 . (canceled)
82 . The method of claim 67 , wherein the bacterial infection is a bacterial pulmonary infection.
83 . The method of claim 82 , wherein the administering comprises administering to the lungs of the patient via a nebulizer, a metered dose inhaler, or a dry powder inhaler.
84 - 92 . (canceled)
93 . The method of claim 67 , wherein the bacterial infection is a Staphylococcus aureus ( S. aureus ) infection.
94 . The method of claim 93 , wherein the S. aureus infection is a methicillin-resistant S. aureus (MRSA) infection.
95 - 127 . (canceled)
128 . The method of claim 67 , wherein the patient is a cystic fibrosis patient.
129 - 132 . (canceled)